Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AHFS | American Hospital Formulary Service |
| BLA | Biologics license application |
| CGM | Continuous glucose monitoring |
| CI | Confidence interval |
| CT | Computed tomography |
| ECOG | Eastern Cooperative Oncology Group |
| ENDO | Annual meeting of the Endocrine Society |
| ENETS | European Neuroendocrine Tumor Society |
| ESMO | European Society for Medical Oncology |
| EU | European Union |
| EUS | Endoscopic ultrasound |
| FDA | U.S. Food and Drug Administration |
| GEP-NET | Gastroenteropancreatic neuroendocrine tumor |
| GLP-1 | Glucagon-like peptide-1 |
| HI | Hyperinsulinism |
| HR | Hazard ratio |
| IGF-1 | Insulin-like growth factor 1 |
| IGF-2, IGF-II | Insulin-like growth factor 2 |
| IND | Investigational new drug application |
| INN | International nonproprietary name |
| IV | Intravenous |
| JNETS | Japan Neuroendocrine Tumor Society |
| KATP | ATP-sensitive potassium channel |
| LAR | Long-acting release |
| MEN 1 | Multiple endocrine neoplasia type 1 |
| mTOR | Mechanistic target of rapamycin |
| NANETS | North American Neuroendocrine Tumor Society |
| NICTH | Non-islet cell tumor hypoglycemia |
| PET | Positron emission tomography |
| PRRT | Peptide receptor radionuclide therapy |
| SEC | U.S. Securities and Exchange Commission |
| SEER | Surveillance, Epidemiology, and End Results Program |
| SMBG | Self-monitored blood glucose |
| SPECT | Single-photon emission computed tomography |
| UK | United Kingdom |
| WHO | World Health Organization |